½ÃÀ庸°í¼­
»óǰÄÚµå
1330121

¼¼°èÀÇ Ç÷Àå À¯µµÃ¼ ½ÃÀå : À¯Çüº°, ¿ëµµº°, Áö¿ªº° - ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2023-2030³â)

Blood Plasma Derivatives Market, By Type and By Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand¢¥ disease, and Other Application) By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç÷ÀåÀº Ç÷¾×ÀÇ ¾×ü ºÎºÐÀÔ´Ï´Ù. Ç÷¾×ÀÇ ¾à 55%´Â Ç÷ÀåÀÌ°í ³ª¸ÓÁö 45%´Â Ç÷Àå ³»¿¡ ºÎÀ¯ÇÏ´Â ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀÔ´Ï´Ù. Ç÷Àå ºÐȹ ±â¼úÀ» »ç¿ëÇÏ¿© Àΰ£ Ç÷ÀåÀ¸·Î ¸¸µé¾îÁø Á¦Ç°Àº Ç÷Àå À¯µµÃ¼(Blood Plasma Derivatives)·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. À̵éÀº »ý¸íÀ» À§ÇùÇÏ´Â ´Ù¾çÇÑ Áúº´ÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù.

½ÃÀå ¿ªÇÐ :

À¯Àü¼º Áúȯ ºÎ´ã Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, Ç÷Àå À¯µµÃ¼¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä, ´Ù¾çÇÑ Ä¡·á ºÐ¾ß¿¡¼­ ¸é¿ª±Û·ÎºÒ¸° »ç¿ë Áõ°¡, Ç÷Àå ¼öÁý ¼¾ÅÍ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È Ç÷Àå À¯µµÃ¼(Blood Plasma Derivatives) ½ÃÀå ¼ºÀåÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.

¿¹¸¦ µé¾î, 2022 ³â 3 ¿ù Sanofi SA¿Í IGM Biosciences, Inc.´Â Çù·ÂÇÏ¿© ¼¼ °¡Áö Á¾¾çÇÐ ¹× ¸é¿ªÇÐ / ¿°Áõ Ç¥Àû¿¡ ´ëÇÑ ¸é¿ª ±Û·ÎºÒ¸° (IgM) Ç×ü ÀÛ¿ëÁ¦¸¦ »ý¼º, °³¹ß, Á¦Á¶ ¹× »ó¿ëÈ­ÇÏ´Â µ¥ Çù·ÂÇß½À´Ï´Ù. ¿£Áö´Ï¾î¸µ Ç×ü´Â Ç¥Àû °áÇÕ ºÎÀ§°¡ 2°³¿¡ ºÒ°úÇÑ ±âÁ¸ IgG Ç×ü¿¡ ºñÇØ 10°³ÀÇ °áÇÕ ºÎÀ§¸¦ °¡Áø Ç×üÀÇ ´Ù¿ø¼ºÀ» °áÇÕÇÑ »õ·Î¿î Á¾·ùÀÇ ÀáÀçÀû Ä¡·áÁ¦¸¦ ³ªÅ¸³À´Ï´Ù.

ÁÖ¿ä Æ¯Â¡

  • Ç÷Àå À¯µµÃ¼(Blood Plasma Derivatives) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð ¹× CAGR(%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ, ¾ïÁ¦ ¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ Ãâ½Ã¿Í ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µî ´ÙÀ½ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î Ç÷Àå À¯µµÃ¼ ½ÃÀå ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµ ÇÕ´Ï´Ù.
  • ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷¿¡´Â Shire Plc., CSL Limited, Octapharma AG, LFB SA, Biotest AG, Grifols, SA, SK Plasma Co., Ltd., Baxter International Inc., Green Cross Corporation, and Fusion Health Care Pvt. Ltd. µîÀÌ Æ÷ÇԵ˴ϴÙ.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • Ç÷Àå À¯µµÃ¼ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶»ç, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº Ç÷Àå À¯µµÃ¼ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç °áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû ¹× ÀüÁ¦ Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦ Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå ¹üÀ§

  • º¸°í¼­ °³¿ä
    • ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • À¯Àü¼º Áúȯ/Èñ±ÍÁúȯÀÇ ºÎ´ãÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡
    • °í¾×ÀÇ Ä¡·áºñ¿Í ºÎÀÛ¿ë
    • Ç÷Àå äÃë ¼¾ÅÍ Áõ°¡
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´¡¤Àμö ½Ã³ª¸®¿À

Á¦4Àå Ç÷Àå À¯µµÃ¼ ½ÃÀå : COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå Ç÷Àå À¯µµÃ¼ ½ÃÀå, À¯Çüº°(2023-2030³â)

  • ¾ËºÎ¹Î
  • Á¦VIIIÀÎÀÚ
  • Á¦IXÀÎÀÚ
  • ¸é¿ª±Û·ÎºÒ¸°
  • °í¸é¿ª±Û·ÎºÒ¸°
  • ±âŸ

Á¦6Àå Ç÷Àå À¯µµÃ¼ ½ÃÀå : ¿ëµµº°(2023-2030³â)

  • Ç÷¿ìº´
  • Àú°¨¸¶±Û·ÎºÒ¸°Ç÷Áõ
  • ¸é¿ª °áÇÌÁõ
  • Æù ºô·¹ºê¶õÆ® º´ (VWD)
  • ±âŸ ¿ëµµ

Á¦7Àå Ç÷Àå À¯µµÃ¼ ½ÃÀå : Áö¿ªº°(2023-2030³â)

  • ºÏ¹Ì
  • ³²¹Ì
  • À¯·´
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • Shire Plc.
  • CSL Limited
  • Octapharma AG
  • LFB SA
  • Biotest AG
  • Grifols, SA
  • SK Plasma Co., Ltd.
  • Baxter International Inc.
  • Green Cross Corporation
  • Fusion Health Care Pvt. Ltd.

Á¦9Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • Á¶»ç ±â°ü ¼Ò°³
LYJ 23.10.04

Plasma is a liquid portion of blood. About 55% of the blood is plasma, and remaining 45% are red blood cells, white blood cells, and platelets that are suspended in the plasma. Products made from human plasma using plasma fractionation techniques are known as plasma derivatives. These are used in the treatment of various life threatening diseases.

Market Dynamics:

Rise in burden of genetic diseases, increasing geriatric population, high demand for blood plasma derivatives, growing use of immunoglobulins in various therapeutic areas, and increasing number of plasma collection centres are major factors expected to augment the growth of the global blood plasma derivatives market during the forecast period.

For instance, in March 2022, Sanofi SA and IGM Biosciences, Inc. collaborated to create, develop, manufacture, and commercialize immunoglobulin (IgM) antibody agonists against three oncology and immunology/inflammation targets. Engineered antibodies represent a new class of potential therapeutics that combine the multi-valency of antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.

Key features of the study:

  • This report provides in-depth analysis of the global blood plasma derivatives market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global blood plasma derivatives market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Shire Plc., CSL Limited, Octapharma AG, LFB S.A., Biotest AG, Grifols, S.A., SK Plasma Co., Ltd., Baxter International Inc., Green Cross Corporation, and Fusion Health Care Pvt. Ltd., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global blood plasma derivatives market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood plasma derivatives market.

Detailed Segmentation:

  • Global Blood Plasma Derivatives Market, By Type:
    • Albumin
    • Factor VIII
    • Factor IX
    • Immunoglobulin
    • Hyperimmune Globulin
    • Other
  • Global Blood Plasma Derivatives Market, By Application:
    • Hemophilia
    • Hypogammaglobulinemia
    • Immunodeficiency Diseases
    • Von Willebrand' disease (VWD)
    • Other Application
  • Global Blood Plasma Derivatives Market, By Geography:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Shire Plc.
    • CSL Limited
    • Octapharma AG
    • LFB S.A.
    • Biotest AG
    • Grifols, S.A.
    • SK Plasma Co., Ltd.
    • Baxter International Inc.,
    • Green Cross Corporation
    • Fusion Health Care Pvt. Ltd.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Application
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in burden of genetic/rare diseases worldwide
    • High cost of treatment/therapy and side effects
    • Increasing number of plasma collection centres
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Blood Plasma Derivatives Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Blood Plasma Derivatives Market, By Type, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Albumin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Factor VIII
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Factor IX
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Immunoglobulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Hyperimmune Globulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

6. Global Blood Plasma Derivatives Market, By Application, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Hemophilia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Hypogammaglobulinemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Immunodeficiency Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Von Willebrand Disease (VWD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Other Application
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

7. Global Blood Plasma Derivatives Market, By Region, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2023-2030,(US$ Bn)

8. Competitive Landscape

  • Shire Plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • CSL Limited
  • Octapharma AG
  • LFB S.A.
  • Biotest AG
  • Grifols, S.A.
  • SK Plasma Co., Ltd.
  • Baxter International Inc.
  • Green Cross Corporation
  • Fusion Health Care Pvt. Ltd.
  • Analyst Views

9. Section

  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦